 Christine McMahon
Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 28 | 2026 | 700 | 4.540 |
Why?
| | Myelodysplastic Syndromes | 5 | 2026 | 170 | 1.520 |
Why?
| | fms-Like Tyrosine Kinase 3 | 5 | 2026 | 51 | 1.370 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 14 | 2026 | 293 | 1.340 |
Why?
| | Aniline Compounds | 3 | 2019 | 120 | 1.240 |
Why?
| | Pyrazines | 3 | 2019 | 94 | 1.240 |
Why?
| | Sulfonamides | 14 | 2026 | 596 | 1.180 |
Why?
| | Azacitidine | 9 | 2026 | 168 | 1.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 7 | 2026 | 703 | 0.990 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 15 | 2026 | 2001 | 0.950 |
Why?
| | Antineoplastic Agents | 5 | 2026 | 2231 | 0.830 |
Why?
| | ras Proteins | 2 | 2026 | 153 | 0.770 |
Why?
| | Transplantation Conditioning | 2 | 2024 | 191 | 0.690 |
Why?
| | Mutation | 11 | 2026 | 4130 | 0.660 |
Why?
| | Clonal Evolution | 1 | 2019 | 47 | 0.560 |
Why?
| | Protein Kinase Inhibitors | 3 | 2019 | 984 | 0.550 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2026 | 889 | 0.530 |
Why?
| | Nuclear Proteins | 4 | 2026 | 745 | 0.510 |
Why?
| | Molecular Targeted Therapy | 2 | 2024 | 444 | 0.490 |
Why?
| | Signal Transduction | 5 | 2026 | 5272 | 0.440 |
Why?
| | Immunotherapy | 1 | 2018 | 672 | 0.390 |
Why?
| | Recurrence | 5 | 2026 | 1151 | 0.360 |
Why?
| | Prognosis | 7 | 2026 | 4383 | 0.350 |
Why?
| | Proto-Oncogene Proteins | 2 | 2025 | 627 | 0.340 |
Why?
| | Sarcoma, Myeloid | 1 | 2026 | 6 | 0.240 |
Why?
| | Aged, 80 and over | 9 | 2026 | 8430 | 0.240 |
Why?
| | Humans | 34 | 2026 | 147293 | 0.230 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2026 | 108 | 0.230 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2025 | 15 | 0.220 |
Why?
| | Activin Receptors, Type II | 1 | 2025 | 12 | 0.220 |
Why?
| | STAT3 Transcription Factor | 2 | 2025 | 215 | 0.220 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2025 | 41 | 0.220 |
Why?
| | Aged | 15 | 2026 | 26514 | 0.210 |
Why?
| | Drug Approval | 1 | 2025 | 93 | 0.210 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 23 | 0.210 |
Why?
| | Middle Aged | 17 | 2026 | 36821 | 0.210 |
Why?
| | Oligonucleotides | 1 | 2025 | 154 | 0.200 |
Why?
| | Treatment Outcome | 9 | 2026 | 11947 | 0.200 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 72 | 0.200 |
Why?
| | Leukocytosis | 2 | 2020 | 32 | 0.190 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2024 | 103 | 0.190 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2024 | 141 | 0.180 |
Why?
| | Recombinant Fusion Proteins | 1 | 2025 | 669 | 0.180 |
Why?
| | Tumor Microenvironment | 1 | 2026 | 748 | 0.170 |
Why?
| | Adult | 15 | 2026 | 41405 | 0.170 |
Why?
| | Survival | 1 | 2019 | 38 | 0.150 |
Why?
| | Male | 17 | 2026 | 73950 | 0.140 |
Why?
| | Disease Management | 2 | 2024 | 654 | 0.140 |
Why?
| | Young Adult | 7 | 2026 | 14437 | 0.140 |
Why?
| | Retreatment | 1 | 2018 | 80 | 0.140 |
Why?
| | Female | 17 | 2026 | 80076 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 1000 | 0.140 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 278 | 0.140 |
Why?
| | Sweet Syndrome | 1 | 2017 | 10 | 0.130 |
Why?
| | Risk Factors | 2 | 2025 | 11017 | 0.130 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2017 | 187 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 539 | 0.110 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 367 | 0.110 |
Why?
| | Spiro Compounds | 2 | 2025 | 17 | 0.110 |
Why?
| | Muscle Proteins | 1 | 2017 | 244 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 323 | 0.110 |
Why?
| | Benzamides | 2 | 2025 | 227 | 0.100 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 88 | 0.090 |
Why?
| | Remission Induction | 2 | 2026 | 310 | 0.090 |
Why?
| | Retrospective Studies | 7 | 2025 | 17560 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2024 | 319 | 0.080 |
Why?
| | Cell Differentiation | 1 | 2019 | 2054 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1339 | 0.080 |
Why?
| | DNA Methylation | 2 | 2026 | 722 | 0.080 |
Why?
| | Neoplastic Stem Cells | 2 | 2025 | 409 | 0.080 |
Why?
| | Leukapheresis | 2 | 2020 | 27 | 0.080 |
Why?
| | Daunorubicin | 1 | 2025 | 25 | 0.060 |
Why?
| | Cytarabine | 1 | 2025 | 66 | 0.060 |
Why?
| | Transplantation, Homologous | 1 | 2026 | 422 | 0.050 |
Why?
| | Piperidines | 1 | 2026 | 224 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3565 | 0.050 |
Why?
| | Splicing Factor U2AF | 1 | 2023 | 18 | 0.050 |
Why?
| | Gene Rearrangement | 1 | 2024 | 156 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 90 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 122 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2023 | 144 | 0.050 |
Why?
| | Pyrimidines | 1 | 2026 | 532 | 0.050 |
Why?
| | Indoles | 1 | 2026 | 510 | 0.050 |
Why?
| | Cell Survival | 1 | 2025 | 1111 | 0.040 |
Why?
| | Stem Cell Transplantation | 1 | 2023 | 189 | 0.040 |
Why?
| | Neoplasms | 1 | 2017 | 2946 | 0.040 |
Why?
| | Graft vs Host Disease | 1 | 2024 | 280 | 0.040 |
Why?
| | RNA Splicing | 1 | 2023 | 285 | 0.040 |
Why?
| | Adolescent | 3 | 2025 | 22825 | 0.040 |
Why?
| | Phosphorylation | 1 | 2025 | 1721 | 0.040 |
Why?
| | Animals | 4 | 2026 | 38410 | 0.040 |
Why?
| | Allografts | 1 | 2021 | 152 | 0.040 |
Why?
| | Mice | 3 | 2025 | 18491 | 0.040 |
Why?
| | Databases, Factual | 1 | 2026 | 1504 | 0.040 |
Why?
| | Calcium | 1 | 2025 | 1197 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2197 | 0.030 |
Why?
| | Dapsone | 1 | 2017 | 8 | 0.030 |
Why?
| | Hematologic Agents | 1 | 2017 | 3 | 0.030 |
Why?
| | Potassium Iodide | 1 | 2017 | 4 | 0.030 |
Why?
| | Filgrastim | 1 | 2017 | 13 | 0.030 |
Why?
| | Colchicine | 1 | 2017 | 21 | 0.030 |
Why?
| | Folic Acid Antagonists | 1 | 2017 | 8 | 0.030 |
Why?
| | Tubulin Modulators | 1 | 2017 | 11 | 0.030 |
Why?
| | Leukopenia | 1 | 2017 | 33 | 0.030 |
Why?
| | Neutrophils | 1 | 2023 | 1135 | 0.030 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2017 | 5 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 2017 | 8 | 0.030 |
Why?
| | Odds Ratio | 1 | 2020 | 1084 | 0.030 |
Why?
| | Arthralgia | 1 | 2017 | 61 | 0.030 |
Why?
| | Janus Kinases | 1 | 2017 | 21 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3216 | 0.030 |
Why?
| | Machine Learning | 1 | 2022 | 596 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 196 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1550 | 0.030 |
Why?
| | Anemia | 1 | 2017 | 192 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2017 | 207 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2890 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3784 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2142 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 487 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2017 | 566 | 0.030 |
Why?
| | Inflammation | 1 | 2017 | 2920 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 6041 | 0.010 |
Why?
| | Child | 1 | 2024 | 22979 | 0.010 |
Why?
|
|
McMahon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|